Jiawei Xianglian Decoction (JWXLD)‎, a Traditional Chinese Medicine (TCM)‎, Alleviates CPT-11-Induced Diarrhea in Mice

Abstract EN

Irinotecan (CPT-11) is used for therapy of various cancers.

However, it has several serious adverse reactions such as diarrhea which is caused by SN-38, the active form of CPT-11.

This study aimed to evaluate the effectiveness of Jiawei xianglian decoction (JWXLD), which has been widely used for the treatment of diarrhea in China.

In this study, a mouse model with delayed diarrhea was generated by CPT-11.

Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were performed to explore intestinal microflora and inflammatory cytokine.

Hematoxylin and eosin (H&E) staining was used to analyze tissue morphology.

We found that 0.12, 0.23, and 0.46 g JWXLD significantly reduced the severity of CPT-11-induced diarrhea.

The levels of Lactobacillus (Lacto) and Bifidobacterium (Bifid) were significantly downregulated by CPT-11, and these effects can be reversed by JWXLD treatment.

Furthermore, JWXLD was observed to decrease the activity of β-glucuronidase (β-GD).

Histopathological data showed that CPT-11 induced severe intestinal mucosal injury, which was characterized as grade 6, and JWXLD significantly alleviated the injury.

In addition, CPT-11 increased the productions of tumor necrosis factor-alpha (TNF-α), tumor necrosis factor-beta (TNF-β), interleukin-6 (IL-6), and interleukin-1 (IL-1), but decreased interleukin-15 (IL-15), interleukin-7 (IL-7), and uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1).

In conclusion, JWXLD can counteract these effects caused by CPT-11 treatment.

JWXLD could alleviate CPT-11-induced diarrhea.